Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 2:00 p.m. EST. Investors can access a live webcast of the presentation on the Investor Relations website. With approximately $1.1 billion in net sales in fiscal 2022, Bio-Techne specializes in high-quality purified proteins, reagent solutions, and diagnostic products, providing tools for research and clinical diagnostics globally.

Bio-Techne Corporation (NASDAQ: TECH) announced a partnership with Cell Signaling Technology (CST) on February 14, 2023, aimed at enhancing research capabilities in molecular signaling pathways. This collaboration introduces Simple Western™ validation for CST antibodies, streamlining the study of critical cellular functions. The Simple Western systems provide rapid results in protein detection, enabling researchers to achieve more accurate and efficient data collection. With over $1.1 billion in net sales generated in fiscal 2022, Bio-Techne is positioned to support advancements in drug discovery through its innovative platforms.

Bio-Techne Corporation (NASDAQ: TECH) reported its financial results for the second quarter of FY2023, showing a 4% increase in organic revenue to $271.6 million. However, GAAP earnings per share (EPS) fell to $0.31 from $0.49 year-over-year due to a prior non-recurring gain. The company experienced a strong performance in its ExoDx Prostate test, with revenues doubling year-over-year. Despite challenges in Biotech funding and currency exchange impacts, growth in the US consumable business and cell therapy portfolio remained robust. Adjusted EPS held steady at $0.47 amid a competitive market environment.

On February 2, 2023, Bio-Techne Corporation (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended December 31, 2022. This dividend will be payable on February 27, 2023 to shareholders of record on February 13, 2023. Bio-Techne, a global leader in life sciences, reported approximately $1.1 billion in net sales for fiscal 2022 and employs around 3,000 staff worldwide. The Board will evaluate future dividends quarterly. The company’s innovative tools and reagents play a critical role in research and diagnostics.

Bio-Techne Corporation (NASDAQ: TECH) announced the appointment of Shane Bohnen as Senior Vice President and General Counsel, effective March 3, 2023. Bohnen succeeds Brenda Furlow, who is retiring after nine years of significant contributions, including establishing the legal and compliance functions and leading corporate sustainability initiatives. Bohnen has over 20 years of legal experience, including his role as Associate General Counsel at Bio-Techne since 2019, where he managed M&A activities and ESG initiatives. Chuck Kummeth, CEO, emphasized Bohnen's extensive knowledge and leadership as vital for the company's growth strategy.

Bio-Techne Corporation (NASDAQ: TECH) launched its ProteinSimple-branded MauriceFlex™ system during the WCBP conference on Jan. 26, 2023, in Washington D.C. This innovative system enables protein charge variant fractionation along with routine cIEF and CE-SDS assays, streamlining protein characterization workflows. MauriceFlex™ distinguishes itself by allowing cIEF-based fractionation without the extensive method development and preparation typically required. A major biotech company showcased the system's capabilities in analyzing charge variant fractions of a therapeutic dual variable domain antibody. According to Will Geist, President of Protein Sciences, MauriceFlex™ accelerates therapeutic molecule analysis, enhancing market readiness.

Bio-Techne Corporation (NASDAQ: TECH) announced a conference call and webcast to discuss its second quarter 2023 financial results on February 2, 2023, at 8:00 a.m. CST. Investors can join the call by dialing 1-877-407-9208 or through the webcast link provided. A recorded replay will be available from 11:00 a.m. CST on February 2 until 11:00 p.m. CST on March 2. The company, noted for high-quality protein and reagent solutions, generated approximately $1.1 billion in net sales in fiscal 2022 and employs around 3,000 people globally.

Bio-Techne Corporation (NASDAQ: TECH) has introduced the RNAscope Plus smRNA-RNA detection assay, expanding its Advanced Cell Diagnostics (ACD) portfolio. This assay allows simultaneous fluorescent detection of small regulatory RNAs and target RNAs within tissue samples at single-cell resolution. Designed for scalability, it supports extensive studies on the Leica Bond Rx platform. The assay enhances the research of oligonucleotide therapies, crucial for developing targeted treatments for various diseases. Bio-Techne reported approximately $1.1 billion in net sales for fiscal 2022.

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST. The presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website. Bio-Techne specializes in manufacturing purified proteins, reagents, and diagnostic products, generating approximately $1.1 billion in net sales in fiscal 2022. The company employs around 3,000 people globally and offers a wide range of scientific products for molecular diagnostics and biological research.